Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1(Glu280Ala) mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial
在哥伦比亚，一项针对认知功能正常的、携带PSEN1(Glu280Ala)突变且有常染色体显性遗传阿尔茨海默病风险的人群的克雷尼珠单抗安全性和有效性研究（API ADAD Colombia试验）：一项2期随机、双盲、安慰剂对照试验
期刊:Lancet Neurology
影响因子:45.5
doi:10.1016/S1474-4422(25)00426-0
Tariot, Pierre N; Lopera, Francisco S; Ríos-Romenets, Silvia; Sink, Kaycee M; Giraldo-Chica, Margarita; Acosta-Baena, Natalia; Villegas, Gustavo; Espinosa, Alejandro; Castaño, Marisol Londoño; Muñoz, Claudia; Ospina, Paula; Bocanegra, Yamile; Tirado, Victoria; Henao, Eliana; Cardona, Eugenia; Luna, Ernesto; Lopez, Hugo; Sánchez, Gregorio; Collazos, Mario Muñoz; Alvarez, Sergio; Aguillón, David; Hu, Nan; Clayton, David; Bittner, Tobias; Schneider, Andres; Dolton, Michael; Poon, Victor; Nguyen, Jonas; Thomas, Ronald G; Schneider, Lon S; Chen, Kewei; Su, Yi; Alexander, Robert C; Quiroz, Yakeel T; Cai, Yuqi; Xu, Yi Ran; Ostaszewski, Beth; Selkoe, Dennis J; Ashton, Nicholas J; Denkinger, Marisa N; Jakimovich, Laura J; Doody, Rachelle S; Langbaum, Jessica B; Reiman, Eric M
